Safety Study for the Treatment of Abdominal Aortic Aneurysms

Phase 2

Terminated

• Conditions: Abdominal Aortic Aneurysms

• Registration Number: NCT00610090
• Lead Sponsor: Duke Vascular, Inc.

Brief Summary

The primary study objective, at this time, is to follow out to 5 years post implant the safety of already enrolled subjects who were treated with the UniFit Aorto-uni-iliac (AUI) Endoluminal Stent Graft (the "study device") for the repair of abdominal aortic aneurysms (AAAs).

Detailed Description

This is a phase II, single-arm, prospective study of the safety of the study device for the repair of AAAs.

The investigator will identify eligible patients and explain the study and study device placement procedure to each patient and/or any available family members. Patients who provide written informed consent will be evaluated for study eligibility within the time period identified under Duration of Treatment. Patients who are confirmed to be eligible, based on screening assessment findings, will be enrolled in the study.

After hospital discharge, patients will attend study center visits at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post-procedure for follow-up evaluations.

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2008-01-24
• Study First Submitted QC: 2008-01-24
• Study First Posted: 2008-02-07
• Status Verified: 2015-05
• Last Update Submitted: 2015-08-23
• Last Update Posted: 2015-08-25
• Primary Completion: 2015-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

• Patient is 18 years of age or older

• Patient has a AAA that meets one of the following criteria:

  1. Aneurysm diameter of greater than 4.5 cm, or less than 4.5 cm with rapid expansion
  2. The aneurysm has a saccular configuration where potential for rupture is increased or has exhibited dissection with potential for rupture at, or compromised flow to, vital structures

• The vessels immediately proximal and distal to the lesion are capable of accommodating the study device

• The access artery diameter and profile of the artery are capable of study device delivery.

• Patient has proximal and distal neck lengths of greater than or equal to 1.0 cm

• Patient is willing and able to comply with the follow-up regime.

• Patient has provided written informed consent.

Exclusion Criteria

• Patient has an aortic diameter greater than 36 mm.
• Patients with ASA score less than 3 and deemed low risk by the Investigator for open surgical repair.
• Patient has an indispensable inferior mesenteric artery.
• Patient has a distal landing zone of < 2 cm in length or > 16 mm in diameter
• Patient has iliac arteries whose tortuosity prevents passage of the introducer catheter.
• If female, patient is pregnant
• Patient has a life expectancy less than two years.
• Patient has an allergy to any of the study device materials
• Patient has coagulopathy or bleeding disorders
• Patient for whom contrast medium or anticoagulation drugs are contraindicated
• Patient has an uncontained rupture of the aneurysm.
• Patient has an active systemic or localized groin infection
• Patient has a connective tissue disease.
• Patient has a GFR < 30 ml/min/1.73m2
• Patient has a circumferential mural thrombus at the implantation site.
• Patient is a candidate for a bifurcated endovascular graft.
• Patient has an aortic trunk with an angle greater than 90°.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Primary Objective	5 year	The primary objective, at this time, is to ensure the safety of already enrolled and treated subjects. The data resulting from this study will not be used for any regulatory or commercialization purpose.; The current sponsor, Duke Vascular, Inc. is requesting closure of this IDE

Trial Locations

Locations (19)

Loma Linda VA; 🇺🇸 Loma Linda, California, United States

UCLA Medical Center; 🇺🇸 Torrance, California, United States

Christiana Hospital; 🇺🇸 Newark, Delaware, United States

Florida Hospital; 🇺🇸 Orlando, Florida, United States

Sacred Heart Hospital; 🇺🇸 Pensacola, Florida, United States

Emory University; 🇺🇸 Atlanta, Georgia, United States

Savannah Vascular Institute; 🇺🇸 Savannah, Georgia, United States

Indiana University Hospital; 🇺🇸 Indianapolis, Indiana, United States

Iowa Heart Center; 🇺🇸 Des Moines, Iowa, United States

University of Massachusetts Medical School; 🇺🇸 Worcester, Massachusetts, United States

Scroll for more (9 remaining)